Amplexd Therapeutics Initiates HPV Therapy Trial

United Therapeutics, a U.S.-based biotechnology company, announced the initiation of a Phase 2 clinical trial in China — Hong Kong for its novel EGCg-based investigational therapy. This therapy targets precancerous cervical lesions associated with high-risk human papillomavirus (hr-HPV). The Hong Kong — Department of Health (Hong Kong) authorized the trial, which is being conducted in collaboration with University of Hong Kong and William, Prince of Wales. The study will evaluate the safety and efficacy of the vaginal suppository formulation in women with ASC-US and low-grade squamous intraepithelial lesions (LSIL) and confirmed hr-HPV infection. Clinical data are expected in Q1 2027. Alia Rahman, CEO of United Therapeutics, highlighted the significant unmet medical need for non-surgical therapies for low-grade lesions, particularly in resource-constrained settings like Asia-Pacific, where cervical cancer is a major public health issue.